Clinical Synopsis of COVID-19

Evolving and Challenging
 
 
Springer (Verlag)
  • 1. Auflage
  • |
  • erschienen am 5. Oktober 2020
  • |
  • 260 Seiten
 
E-Book | PDF mit Adobe-DRM | Systemvoraussetzungen
978-981-15-8681-1 (ISBN)
 

Corona virus disease or COVID-19 or SARS-CoV-2 infection is the latest pandemic that has affected humans globally. The disease has manifested itself in several forms and is now the focus of research worldwide.

This book covers all the clinical aspects of the novel corona virus disease, COVID-19, which is one of the most contagious diseases ever known. It includes topics related to basic sciences, such as the virology and pathophysiology of the SARS-CoV-2 disease. It includes chapters related to symptomatology of the disease and making diagnosis, preparation of the health care workers to deal with this global pandemic. The book includes chapters on anesthetic and intensive care management of COVID-19 disease victims as these topics are of vast importance. Additionally, it includes a chapter giving insight in to the ethical aspects of the issues raised regarding disposal of bodies of the victims, as this pandemic has taken many lives across the world. It includes a chapter on special considerations to patient population such as geriatrics, pediatrics and pregnant women.

The book serves as a useful resource for practitioners and clinicians in any field of medicine. It is also relevant for residents, trainees, fellows pursuing their courses in emergency medicine, anesthesia and critical care as well as postgraduates and even undergraduates.  

The book will serve as a ready-reckoner and useful guide for physicians from varied specialties during their clinical practice.



Dr Hemanshu Prabhakar is a Professor at the Department of Neuroanesthesiology and Critical Care at All India Institute of Medical Sciences (AIIMS), New Delhi, India. He received his training in Neuroanesthesia and completed his PhD in the same institute. He is the first Indian to be awarded the degree of PhD in Neuroanesthesia, in the country. He is a recipient of the AIIMS Excellence Award 2012 for his notable contribution to academia and has published over 250 papers in peer-reviewed national and international journals. Dr. Prabhakar is a reviewer for various national and international journals, and is also a review author for the Cochrane Collaboration. He has special interest in evidence-based practice of neuroanesthesia. Dr. Prabhakar is a member of various national and international neuroanesthesia societies and is past secretary of the Indian Society of Neuroanesthesia and Critical Care. He is an invited speaker for various national and international conferences. He is on the editorial board of the Indian Journal of Palliative Care and is the past executive editor of the Journal of Neuroanaesthesiology and Critical Care. He is the first Indian to publish international books in the speciality of neuroanesthesia. He is an active member of the of the SNACC (Society of Neurosciences in Anesthesiology and Critical Care), NCS (Neurocritical Care Society) and NACCS (Neuroanaesthesia and Critical Care Society of Great Britain and Ireland) . He was featured in the Limca Book of Records 2019 for publishing several books on a niche subject.

Dr Indu Kapoor is Associate Professor in the Department of Neuroanaesthesiology and Critical Care at All India Institute of Medical Sciences (AIIMS), New Delhi, India. She received her training in neuroanesthesia at the same institute. Dr. Kapoor has a special interest in evidence-based practice in neuroanesthesia. She has several publications in national and international journals to her credit and has written numerous chapters for various national and international books. She is also a reviewer of national and international journals and a review author for the Cochrane Collaboration. She is a recipient of many awards. Additionally, she is a member of various national societies and has been an invited faculty member at various national conferences. She is an editor of several books on the subject of neuroanesthesia and neurocritical care.

Dr Charu Mahajan is Associate Professor in the Department of Neuroanaesthesiology and Critical Care at All India Institute of Medical Sciences (AIIMS), New Delhi, India. After completing MD in Anesthesia, she completed DM in neuroanesthesia at AIIMS and later joined AIIMS as a faculty member. She has over a decade of research experience and has received various awards for scientific presentations. She has several publications in various national and international journals, edited several books and authored chapters in many books. She is a reviewer for the Cochrane Collaboration. Dr. Mahajan is also a member of various scientific societies and is a reviewer for several reputable scientific journals.

  • Englisch
  • Singapore
  • |
  • Singapur
  • 4,70 MB
978-981-15-8681-1 (9789811586811)
weitere Ausgaben werden ermittelt
  • Intro
  • Preface
  • Acknowledgments
  • Contents
  • About the Editors
  • 1: Introduction: History of Coronavirus Disease Pandemic
  • References
  • 2: Basic Virology and Pathophysiology of COVID-19
  • 2.1 Introduction
  • 2.2 Classification
  • 2.3 Jump from Animals to Humans
  • 2.4 Morphology of SARS-CoV-2
  • 2.5 Genome of the Novel Coronavirus
  • 2.6 Life Cycle of SARS-CoV-2
  • 2.7 Host Immune Response
  • 2.8 Immune Evasion by Coronaviruses
  • 2.9 Pathogenesis
  • 2.10 Conclusion
  • References
  • 3: Clinical Manifestations of Corona Virus Disease
  • 3.1 Introduction
  • 3.2 Clinical Manifestations of COVID-19
  • 3.2.1 General Systemic Manifestations
  • 3.2.2 Respiratory Manifestations
  • 3.2.3 Neurological Manifestations
  • 3.2.4 Cardiovascular Manifestations
  • 3.2.5 Gastrointestinal and Hepatic Manifestations
  • 3.2.6 Hematological and Biochemical Manifestations
  • 3.2.7 Ophthalmic Manifestations
  • 3.2.8 Dermatological Manifestations
  • 3.3 Summary
  • References
  • 4: Diagnostic Approach to a Patient with Coronavirus Disease
  • 4.1 Introduction
  • 4.2 Diagnostic approach to Covid-19
  • 4.3 Molecular Assays for Viral Nucleic Acid Detection
  • 4.3.1 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
  • 4.3.2 Isothermal Nucleic Acid Amplification
  • 4.3.3 Microarray-Based Hybridization Techniques
  • 4.3.4 Amplicon-Based Metagenomic Sequencing
  • 4.4 Serological or Immunological Assays
  • 4.4.1 Enzyme-Linked Immunosorbent Assay (ELISA)
  • 4.4.2 Lateral Flow Immunoassay (LFIA)
  • 4.4.3 Luminescent Immunoassay
  • 4.4.4 Neutralization Assay
  • 4.4.5 Biosensor Test
  • 4.5 Conclusion
  • References
  • 5: Therapeutic Approach to Coronavirus Disease
  • 5.1 Introduction to COVID-19 Therapeutics
  • 5.2 Antiviral Agents
  • 5.2.1 Favipiravir
  • 5.2.2 Remdesivir
  • 5.2.3 Lopinavir/Ritonavir
  • 5.2.4 Hydroxychloroquine or Chloroquine with or Without Azithromycin
  • 5.3 Immunomodulatory Agents
  • 5.3.1 Interleukin 6 Inhibitors
  • 5.3.2 Corticosteroids
  • 5.3.3 Anakinra
  • 5.3.4 Colchicine
  • 5.3.5 Convalescent Plasma
  • 5.3.6 Vitamins and Minerals
  • 5.4 Controversial Agents
  • 5.4.1 Renin Angiotensin Aldosterone Inhibitors
  • 5.4.2 Non-steroidal Anti-inflammatory Drugs
  • 5.5 Summary and Future Research
  • References
  • 6: Anesthetic Consideration for Patients with Corona Virus Disease
  • 6.1 Preoperative Evaluation
  • 6.2 Operating Room Organization and Self-Protection
  • 6.3 Airway Management
  • 6.4 General Anesthesia
  • 6.5 Regional Anesthesia
  • 6.6 Fluid Management and Associated Therapy
  • 6.7 Postoperative Management
  • References
  • 7: Intensive Care Management of Corona Virus Disease
  • 7.1 Structural and Functional Features of COVID-19 ICU
  • 7.1.1 Structural Characteristics
  • 7.1.2 Equipment (Ventilators/Monitors/Devices)
  • 7.1.3 Human Resources
  • 7.2 Criteria for COVID-19 ICU Admission
  • 7.3 Respiratory Support
  • 7.3.1 Noninvasive Respiratory Support
  • 7.3.2 Invasive Mechanical Ventilation
  • 7.3.3 Prone Position
  • 7.3.4 Extracorporeal Membrane Oxygenation (ECMO)
  • 7.3.5 Tracheostomy
  • 7.3.6 Lung Ultrasound
  • 7.4 Management of Hemodynamic Failure
  • 7.4.1 Shock
  • 7.4.2 Fluid Therapy and Vasopressors
  • 7.4.3 Basic and Advanced Life Support in COVID-19 Adult Patients
  • 7.4.4 Acute Kidney Injury (AKI) and Continuous Renal Replacement Therapy (CRRT)
  • 7.5 Adjuvant Therapies
  • 7.5.1 Coagulation
  • 7.5.2 Co-Infections and Antibiotics Use in COVID-19 ICU Patients
  • 7.5.3 Steroids
  • 7.6 Communication Strategies in the ICU at the Time of COVID-19 Pandemic
  • 7.6.1 Basic Principles: Honesty, Punctuality, Accountability, Trust
  • 7.6.2 Content of the Communication
  • 7.6.3 Checklist for Communication
  • 7.6.4 Videocalls and Other Communication Strategies
  • 7.6.5 Communication at the End of Life and Grief
  • References
  • 8: Complications of Corona Virus Disease
  • 8.1 Introduction
  • 8.2 COVID-19-Related Pulmonary Complications
  • 8.3 COVID-19-Related Extrapulmonary Complications
  • 8.3.1 Hematological
  • 8.3.2 Cardiovascular
  • 8.3.3 Neurological
  • 8.3.4 Renal
  • 8.3.5 Endocrine
  • 8.3.6 Hepatic and Gastrointestinal
  • 8.3.7 Others (Musculoskeletal, Ophthalmological, Dermatological)
  • 8.4 Long-Term Complications
  • 8.4.1 Treatment-Related Complications
  • 8.4.1.1 Medications
  • 8.4.1.2 ICU-Related Complications
  • 8.4.1.3 Post-ICU Discharge Syndrome
  • 8.5 Other Possible Long-Term Complications
  • References
  • 9: Psychosocial Issues Related to Corona Virus Disease
  • 9.1 Introduction
  • 9.1.1 Psychosocial Issues Related to Corona Virus Disease
  • 9.1.1.1 Corona Virus Disease and Effect on General Population
  • 9.1.2 Corona Virus Disease and Healthcare Workers
  • 9.1.3 Corona Virus Disease and Children
  • 9.2 Signs and Symptoms
  • 9.3 Interventions
  • References
  • 10: Trauma Care and Coronavirus Disease
  • 10.1 Introduction
  • 10.2 Epidemiology of Trauma Amidst the COVID-19 Pandemic
  • 10.3 Trauma Care During a Pandemic
  • 10.3.1 Prehospital Measures
  • 10.3.2 Hospital Trauma Bay
  • 10.3.3 COVID-19 Triage/Rule out
  • 10.3.4 Transport of the Patient
  • 10.4 Surgical Interventions (Fig. 10.1)
  • 10.4.1 Blood Products
  • 10.4.2 ICU
  • 10.4.3 Rehabilitation and Out-Patient Services
  • 10.5 COVID-19 in the Injured Patient
  • 10.6 Conclusion
  • 10.7 Summary Points
  • References
  • 11: Pregnant Patients and COVID-19
  • 11.1 Introduction
  • 11.2 Background
  • 11.2.1 Epidemiology in the Obstetric Population
  • 11.2.2 Patient Characteristics
  • 11.3 COVID-19 Disease Manifestations in Pregnancy
  • 11.4 Management of COVID-19 Disease in Pregnancy
  • 11.4.1 Maternal Hemodynamic Goals
  • 11.4.2 Vasopressor Choice in Pregnancy
  • 11.4.3 ARDS Management in Pregnancy
  • 11.4.4 Extracorporeal Life Support (ECLS)/Extracorporeal Membrane Oxygenator (ECMO)
  • 11.4.5 Thromboembolic Disease
  • 11.5 Antenatal Considerations
  • 11.5.1 Fetal Monitoring and Interventions
  • 11.5.2 Corticosteroids, Pregnancy Category B
  • 11.5.3 Intrapartum Fever
  • 11.5.4 Preterm Labor
  • 11.5.5 Nutrition and Glucose Control
  • 11.6 Timing and Mode of Delivery
  • 11.7 Safety of Common Therapies for COVID-19 Disease in Pregnancy (Table 11.2)
  • 11.7.1 Convalescent Plasma
  • 11.8 Uterotonics and Postpartum Hemorrhage (PPH)
  • 11.9 Anesthetic Management
  • 11.9.1 Neuraxial Anesthesia
  • 11.9.2 General Anesthesia for Cesarean Delivery
  • 11.10 Conclusions
  • References
  • 12: Pediatric Patients and COVID-19
  • 12.1 Introduction
  • 12.2 Background
  • 12.2.1 Epidemiology
  • 12.2.2 Presentation of Symptoms
  • 12.2.3 Special Considerations: Pediatric
  • 12.2.4 Special Considerations: Neonatal
  • 12.3 Anesthetic Consideration
  • 12.4 Critical Care Management
  • 12.5 Conclusion
  • References
  • 13: Geriatric Patients and COVID-19
  • 13.1 Introduction
  • 13.1.1 Background
  • 13.2 Clinical Considerations
  • 13.2.1 Diagnosis and Clinical Presentation
  • 13.2.2 Frailty and COVID-19 Outcomes
  • 13.2.3 Anesthetic Considerations
  • 13.2.3.1 Perioperative Anesthesiologic Evaluation
  • 13.2.3.2 General Anesthesia
  • 13.2.3.3 Regional Anesthesia
  • 13.2.4 Treatment
  • 13.2.5 Recent Advances in the Treatment of Coronavirus
  • 13.2.6 Outcomes
  • References
  • 14: Control of Spread of Coronavirus Disease
  • 14.1 Transmission of Coronavirus
  • 14.2 Infection Prevention and Control Practices in COVID-19
  • 14.2.1 Screening and Triage
  • 14.2.2 Source Control
  • 14.2.3 Universal Testing
  • 14.2.4 Engineering Controls
  • 14.2.5 Administrative Measures
  • 14.2.6 Patient Placement
  • 14.2.7 Personal Protective Equipment
  • 14.2.8 Specific Precautions for Aerosol-Generating Procedures
  • 14.2.9 Environmental Infection Control
  • 14.2.10 Quarantine
  • 14.2.11 Discontinuing Infection Precautions
  • 14.2.12 Conclusion
  • References
  • 15: Ethical Issues Related to Coronavirus Disease
  • 15.1 Rights and Duties of Personnel
  • 15.2 Allocation of Scarce Resources
  • 15.3 Shortage of Personal Protective Equipment
  • 15.4 End of Life and Palliative Care
  • 15.5 Cardiopulmonary Resuscitation
  • 15.6 Research and Data Sharing
  • 15.7 Telemedicine
  • 15.8 Ethical Use of Alternative Medicine
  • 15.9 Conclusion
  • Bibliography
  • 16: Webliography
  • 16.1 Society Guidelines
  • 16.1.1 Anesthesiology
  • 16.1.2 Cardiovascular Medicine
  • 16.1.3 Emergency Medicine
  • 16.1.4 Endocrinology and Diabetes
  • 16.1.5 Gastroenterology and Hepatology
  • 16.1.6 Infectious Diseases
  • 16.1.7 Nephrology and Hypertension
  • 16.1.8 Neurosciences
  • 16.1.9 Obstetrics, Gynecology, and Women's Health
  • 16.1.10 Pediatrics
  • 16.1.11 Psychiatry
  • 16.1.12 Pulmonary and Critical Care Medicine
  • 16.1.13 Solid Organ Transplantation
  • 16.1.14 Surgery
  • 16.2 International Public Health and Government Guidelines
  • 16.3 Journals
  • 16.4 Others

Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

128,39 €
inkl. 7% MwSt.
Download / Einzel-Lizenz
PDF mit Adobe-DRM
siehe Systemvoraussetzungen
E-Book bestellen